- Home
- SANG vs NYXH Comparison
SANG vs NYXH Comparison
Compare SANG & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- NYXH
- Stock Information
- Founded
- SANG 1984
- NYXH 2009
- Country
- SANG Canada
- NYXH Belgium
- Employees
- SANG N/A
- NYXH N/A
- Industry
- SANG Computer Software: Programming Data Processing
- NYXH Medical/Dental Instruments
- Sector
- SANG Technology
- NYXH Health Care
- Exchange
- SANG Nasdaq
- NYXH Nasdaq
- Market Cap
- SANG 168.6M
- NYXH 185.5M
- IPO Year
- SANG 2021
- NYXH 2021
- Fundamental
- Price
- SANG $4.98
- NYXH $5.77
- Analyst Decision
- SANG
- NYXH Strong Buy
- Analyst Count
- SANG 0
- NYXH 3
- Target Price
- SANG N/A
- NYXH $15.00
- AVG Volume (30 Days)
- SANG 9.5K
- NYXH 86.7K
- Earning Date
- SANG 11-05-2025
- NYXH 11-05-2025
- Dividend Yield
- SANG N/A
- NYXH N/A
- EPS Growth
- SANG N/A
- NYXH N/A
- EPS
- SANG N/A
- NYXH N/A
- Revenue
- SANG $236,692,000.00
- NYXH $5,793,306.00
- Revenue This Year
- SANG N/A
- NYXH $85.62
- Revenue Next Year
- SANG $5.48
- NYXH $320.09
- P/E Ratio
- SANG N/A
- NYXH N/A
- Revenue Growth
- SANG N/A
- NYXH 2.94
- 52 Week Low
- SANG $4.08
- NYXH $4.35
- 52 Week High
- SANG $7.99
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- SANG 46.11
- NYXH 51.76
- Support Level
- SANG $4.68
- NYXH $4.36
- Resistance Level
- SANG $5.23
- NYXH $6.20
- Average True Range (ATR)
- SANG 0.23
- NYXH 0.35
- MACD
- SANG -0.01
- NYXH 0.09
- Stochastic Oscillator
- SANG 42.66
- NYXH 53.19
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.